A Conversation with AAPS executive director John Lisack, Jr.
A PharmaManufacturing.com Exclusive
Deciphering FDA Acronyms
A handy guide to FDA compliance terms
New Compounding Bill: Win for Personalized Meds or Threat to Patient Safety?
Critics claim that the new bill will do the opposite of what it was intended to do, instead blurring the lines between compounders and drug manufacturers.
- The Biosimilar Name Game